Amur Minerals Corporation (ticker: AMMCF) operates as a cash shell following the divestiture of its mineral exploration assets; it pursues reverse takeover opportunities in the healthcare sector, notably through the acquisition of Extruded Pharmaceuticals Ltd, a UK-based drug delivery technology company focused on enhancing cancer treatments for solid tumors via local chemotherapy delivery. The company's principal former asset was the Kun-Manie nickel-copper sulphide project in Russia's Far East, encompassing nickel, copper, cobalt, platinum group metals including platinum and palladium, gold, and silver deposits across five wholly-owned deposits spanning 36 square kilometers in Amur Oblast; engineering studies confirmed economically viable open-pit and underground mining with flotation processing capabilities positioning it as a potential major global sulphide nickel producer. Founded in 2004 and headquartered in Road Town, British Virgin Islands, Amur Minerals previously concentrated on mineral property evaluation and development exclusively in the Far East of Russia. In March 2023, the company completed the sale of Kun-Manie to Bering Metals LLC for US$35 million, received in full by May 2024, transitioning it to cash shell status and relieving it of ongoing Russian project obligations including the mine plan development. In May 2024, shareholders approved a reverse takeover of Extruded Pharmaceuticals for GBP5.5 million in shares, alongside a name change to CRISM Therapeutics Corp, a 1-for-160 share consolidation, board changes, and re-admission to AIM; the target company's lead product, ChemoSeed, involves implanting chemotherapy directly into tumors such as high-grade gliomas, with plans for a Clinical Trial Application in H2 2024 and Phase II trials in Q4 2025. Further, discussions with Ascent Resources plc for a potential takeover ended in August 2023, and the company reported a pretax profit of USD512,000 in 2023 versus a prior-year loss.